// App-Quantinova.ai

: OUTCOME OF FLUDARABINE-BUSULFAN-ANTI THYMOCYTE GLOBULIN (FLU-BU-ATG) CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPIETIC STEM CELL TRANSPLANTATION

Researchers

Presenter

  • Ahmed Askar

Principal Investigators

  • Moussab Damlaj

  • Mohesen Alzahrani

  • Ayman Alhejazi

  • Giamal Gmati

  • Bader Alahmari

  • Khadeja Abuelgasim

  • Hind Salama

  • Farhan Khalid

  • Muhammad Qureshi

  • Muhammad Almuhayni

  • Inam Shehabeddine

  • Ismat Kamran

  • Mohsen Alhazmi

  • Hind Shatry

  • May Anne Mendoza

  • Ramesh Vishwakarma

  • Mohammed Hussein

Medical Centers

  • Division of Adult Hematology & SCT,King Abdulaziz Medical City,Riyadh,Saudi Arabia;King Abdullah International Medical Research Center,Riyadh,Saudi Arabia;King Saud bin Abdulaziz University for Health Sciences,Riyadh,Saudi Arabia;Saudi Society of Blood & Marrow Transplantation (SSBMT),Riyadh,Saudi Arabia

  • Biostatistics and Bioinformatics, King Abdullah International Medical Research Center. King Saud bin Abdulaziz University of Health Sciences,Riyadh,Saudi Arabia

  • Division of Adult Hematology & SCT,King Abdulaziz Medical City,Riyadh,Saudi Arabia;King Abdullah International Medical Research Center,Riyadh,Saudi Arabia;King Saud bin Abdulaziz University for Health Sciences,Riyadh,Saudi Arabia

  • King Abdullah International Medical Rearch Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

Locations

  • Saudi Arabia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Busulfan

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved